4 withdrawn. 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Withdrawn 4 |
Follow Relapsing Multiple Sclerosis: new trials by email Literature Review of Relapsing Multiple Sclerosis trials Research Report on Relapsing Multiple Sclerosis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Pirtobrutinib (LY3527727 [LOXO-305]) Versus Placebo in Participants With Relapsing Multiple Sclerosis Placebo, Pirtobrutinib - Relapsing Multiple Sclerosis, Multiple Sclerosis | Phase 2 | Withdrawn | Loxo Oncology, Inc. | 2024-05-01 | 2024-03-27 | |
| A Study of Mitoxantrone Hydrochloride Liposome Injection for Relapsing Multiple Sclerosis Mitoxantrone Hydrochloride Liposome Injection - Relapsing Multiple Sclerosis | Phase 2 | Withdrawn | CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. | 2022-08-01 | 2022-12-15 | |
| Study to Evaluate Oral BIIB061 Added to Interferon-beta1 (IFN-β1) or Glatiramer Acetate in Relapsing Multiple Sclerosis (RMS) Placebo, BIIB061, Interferon-beta1 - Relapsing Multiple Sclerosis | Phase 2 | Withdrawn | Biogen | 2021-06-30 | 2023-06-01 | |
| A Multinational, Randomized, Double-blind, Parallel-group, Placebo-controlled Study Assessing the Safety and Tolerability Laquinimod 0.6, Laquinimod 1.2, Glatiramer Acetate or interferon-beta+ Placebo - Relapsing Multiple Sclerosis | Phase 2 | Withdrawn | Teva Branded Pharmaceutical Products R&D, Inc. | 2012-03-01 | 2013-08-27 |
Autoimmune Diseases (1) · Autoimmune Diseases of the Nervous System (1) · Demyelinating Autoimmune Diseases, CNS (1) · Demyelinating Diseases (1) · Immune System Diseases (1) · Nervous System Diseases (1)
Glatiramer Acetate (2) · Coat Protein Complex I (1) · Interferon beta-1a (1) · Interferon beta-1b (1) · Interferon-beta (1) · peginterferon beta-1a (1) · pirtobrutinib (1)
Biogen (1) · CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. (1) · Loxo Oncology, Inc. (1) · Teva Branded Pharmaceutical Products R&D, Inc. (1)
China (1) · Puerto Rico (1) · United States (1)
Ralf Gold, MD (1)
2019 (1)